Evidence map›Paper›PMID 30226609›Full record

ArticleOncology reports2018

hsa‑miR‑24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c‑Myc/epithelial‑mesenchymal transition axis.

Bojin Su, Tao Xu, Jeff P Bruce, Kenneth W Yip, Ning Zhang, Zeli Huang, Guoyi Zhang, Fei-Fei Liu, Jiyong Liang, Huiling Yang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Bojin SuDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China.
Tao XuDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China.
Jeff P BruceDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
Kenneth W YipDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
Ning ZhangDepartment of Radiation Oncology, Cancer Center, First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.
Zeli HuangDepartment of Radiation Oncology, Cancer Center, First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.
Guoyi ZhangDepartment of Radiation Oncology, Cancer Center, First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.
Fei-Fei LiuDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
Jiyong LiangDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huiling YangDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China.
François X ClaretDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
First People's Hospital of Foshan · CNSun Yat-sen University · CNUniversity of Toronto · CAThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Distant metastasis is the major contributor to treatment failure and mortality in patients with nasopharyngeal carcinoma (NPC). The lack of effective treatment strategies for metastatic NPC is the major cause for the low survival rate. Therefore, it is crucial to understand the molecular mechanisms underlying NPC metastasis and to identify potential biomarkers for targeted therapy. MicroRNA (miRNAs or miRs) have been shown to play an important role in tumorigenesis and metastasis. In the present study, we aimed to evaluate the significance of hsa‑miR‑24 in NPC metastasis. Significantly lower hsa‑miR‑24 levels were observed in NPC metastatic tumors and higher hsa‑miR‑24 levels were associated with longer progression‑free and metastasis‑free survival durations. hsa‑miR‑24 overexpression inhibited cell proliferation, invasion and migration. Using bioinformatics approaches together with functional luciferase reporter assays, we demonstrated that the c‑Myc 3'‑UTR was a direct target of hsa‑miR‑24 in regulating NPC metastasis. Protein profiling analysis revealed that a high c‑Myc expression was inversely associated with metastasis‑free overall survival and with epithelial‑mesenchymal transition (EMT). Furthermore, the overexpression of hsa‑miR‑24 decreased NPC cell invasive ability induced by the overexpression of c‑Myc, associated with EMT epithelial marker (E‑cadherin) restoration. Thus, on the whole, the findings of this study demonstrate that hsa‑miR‑24 suppresses metastasis in NPC by regulating the c‑Myc/EMT axis, suggesting that hsa‑miR‑24 may be used as a prognostic factor and as a novel target for the prevention of NPC metastasis.

Indexed as

AgedCarcinomaCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMiddle AgedNasopharyngeal CarcinomaNeoplasm InvasivenessNeoplasm MetastasisProto-Oncogene Proteins c-mycMicroRNAsMIRN24 microRNA, humanProto-Oncogene Proteins c-myc

Identifiers

PMID30226609
PMCPMC6151896
OpenAlexW2889750947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.